AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa + foscarbidopa), in the European Union (EU) for the treatment of advanced Parkinson’s disease (PD). The therapy is indicated for patients experiencing severe motor fluctuations, hyperkinesia, or dyskinesia, and when other treatments fail to adequately control symptoms. The launch is backed by positive Phase I and III clinical data and follows regulatory approval received in 2022.
AbbVie positions Produodopa as the first and only subcutaneous 24-hour continuous infusion levodopa-based therapy for this specific indication. The treatment utilizes a wearable pump to ensure uninterrupted delivery of the dopamine prodrug, preventing depletion of the neurotransmitter in the central nervous system (CNS) and extending the duration of symptom control.- Flcube.com
